<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7518803\results\search\disease\results.xml">
  <result pre="and treatments of myocardial injury in patients with corona virus" exact="disease" post="2019 PengWenyiadWuHaobTanYancLiMeidYangDachunaâ�ŽLiShuangaâ�Ž[a], [b], [c], [d], â�ŽCorresponding authors at: Cardiology"/>
  <result pre="PengWenyiadWuHaobTanYancLiMeidYangDachunaâ�ŽLiShuangaâ�Ž[a], [b], [c], [d], â�ŽCorresponding authors at: Cardiology Dept, The" exact="General" post="Hospital of Western Theater Command, Chengdu Military General Hospital,"/>
  <result pre="Dept, The General Hospital of Western Theater Command, Chengdu Military" exact="General" post="Hospital, 270# Tianhui Road, Jinniu District, Chengdu 610083, Sichuan"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="long as the COVID-19 resource centre remains active. Abstract The" exact="infection" post="epidemic event of the severe acute respiratory syndrome coronavirus"/>
  <result pre="remains active. Abstract The infection epidemic event of the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) was formally declared a"/>
  <result pre="active. Abstract The infection epidemic event of the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) was formally declared a pandemic"/>
  <result pre="Abstract The infection epidemic event of the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) was formally declared a pandemic by"/>
  <result pre="pandemic by World Health Organization on March 11th, 2020. Corona" exact="Virus Disease" post="2019 (COVID-19) is caused by SARS-CoV-2, a new type"/>
  <result pre="by World Health Organization on March 11th, 2020. Corona Virus" exact="Disease" post="2019 (COVID-19) is caused by SARS-CoV-2, a new type"/>
  <result pre="type of coronavirus, which has high contagion and mainly causes" exact="respiratory" post="symptoms. With the increase in confirmed cases, however, the"/>
  <result pre="respiratory symptoms. With the increase in confirmed cases, however, the" exact="infection" post="symptoms turn to be diverse with secondary or first"/>
  <result pre="cases, however, the infection symptoms turn to be diverse with" exact="secondary" post="or first clinical symptoms relating to damage of the"/>
  <result pre="secondary or first clinical symptoms relating to damage of the" exact="cardiovascular" post="system and changes of myocardial enzyme spectrum, cardiac troponin"/>
  <result pre="damage, means that the overall health burden caused by SARS-CoV-2" exact="infection" post="may be under-estimated because COVID-19 patients developed cardiovascular system"/>
  <result pre="by SARS-CoV-2 infection may be under-estimated because COVID-19 patients developed" exact="cardiovascular" post="system injury are more likely to become serious. The"/>
  <result pre="cardiomyocytes, down-regulated angiotensin-converting enzyme 2 (ACE2) expression, excessive inflammatory response," exact="hypoxia" post="and adverse drug reaction, are closely related to the"/>
  <result pre="combination with recently published medical data of patients having SARS-CoV-2" exact="infection" post="and the latest studies, the manifestations of damage to"/>
  <result pre="infection and the latest studies, the manifestations of damage to" exact="cardiovascular" post="system by COVID-19, possible pathogenic mechanisms and advances of"/>
  <result pre="a public health emergency throughout the world. â€¢Apart from typical" exact="respiratory" post="syndrome, cardiovascular injury is also parallel to the confirmed"/>
  <result pre="health emergency throughout the world. â€¢Apart from typical respiratory syndrome," exact="cardiovascular" post="injury is also parallel to the confirmed cases. â€¢The"/>
  <result pre="the novel coronavirus (2019-nCoV) had been officially classified as severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization"/>
  <result pre="novel coronavirus (2019-nCoV) had been officially classified as severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO)"/>
  <result pre="coronavirus (2019-nCoV) had been officially classified as severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared"/>
  <result pre="The World Health Organization (WHO) declared that the novel coronavirus" exact="infection" post="was named coronavirus disease 2019 (COVID-19) [1]. By March"/>
  <result pre="(WHO) declared that the novel coronavirus infection was named coronavirus" exact="disease" post="2019 (COVID-19) [1]. By March 11, 2020, more than"/>
  <result pre="S type, which account for 70% and 30% of the" exact="viral" post="population, respectively [5]. In general, SARS-CoV-2 first causes pneumonia"/>
  <result pre="the viral population, respectively [5]. In general, SARS-CoV-2 first causes" exact="pneumonia" post="via the respiratory tract. The main symptoms are fever,"/>
  <result pre="respectively [5]. In general, SARS-CoV-2 first causes pneumonia via the" exact="respiratory" post="tract. The main symptoms are fever, dry cough, fatigue"/>
  <result pre="of the lungs. While most patients with COVID-19 present with" exact="respiratory" post="symptoms as the primary clinical manifestations, some patients present"/>
  <result pre="most patients with COVID-19 present with respiratory symptoms as the" exact="primary" post="clinical manifestations, some patients present with cardiovascular symptoms, including"/>
  <result pre="symptoms as the primary clinical manifestations, some patients present with" exact="cardiovascular" post="symptoms, including palpitations and chest tightness, as the initial"/>
  <result pre="manifestations, some patients present with cardiovascular symptoms, including palpitations and" exact="chest" post="tightness, as the initial symptoms. Therefore, it is essential"/>
  <result pre="the initial symptoms. Therefore, it is essential to investigate SARS-CoV-2â€&quot;related" exact="cardiovascular" post="symptoms and potential mechanisms and search for potential treatment"/>
  <result pre="facilitate epidemic prevention and control. 2 SARS-CoV-2-related cardiac injury 2.1" exact="Acute" post="cardiac injury With the increase in confirmed cases, acute"/>
  <result pre="2.1 Acute cardiac injury With the increase in confirmed cases," exact="acute" post="cardiac injury is not rare. Early COVID-19 case reports"/>
  <result pre="5 of the first 41 confirmed COVID-19 patients (12%) had" exact="acute" post="myocardial injury, characterized by high-sensitivity cardiac troponin I (hs-cTnI)â€¯&amp;gt;â€¯28â€¯pg/mL;"/>
  <result pre="(hs-cTnI)â€¯&amp;gt;â€¯28â€¯pg/mL; of these patients, 4 had severe forms of the" exact="disease" post="[6]. Later, in another clinical cohort of COVID-19, CK"/>
  <result pre="analyzed 138 hospital patients and found that 10 (7.2%) had" exact="acute" post="cardiac injury. In addition, critically ill patients had significantly"/>
  <result pre="and hs-cTnI, suggesting that severe patients were more susceptible to" exact="acute" post="myocardial injury [8]. Tachycardia, bradycardia and arrhythmia are common"/>
  <result pre="more susceptible to acute myocardial injury [8]. Tachycardia, bradycardia and" exact="arrhythmia" post="are common in SARS. For example, in a study"/>
  <result pre="121 SARS patients, tachycardia was observed in 87 patients (71.9%)," exact="transient" post="bradycardia in 18 patients (4.9%) and atrial fibrillation in"/>
  <result pre="87 patients (71.9%), transient bradycardia in 18 patients (4.9%) and" exact="atrial fibrillation" post="in 1 patient, suggesting transient heart injury [9]. It"/>
  <result pre="patients (71.9%), transient bradycardia in 18 patients (4.9%) and atrial" exact="fibrillation" post="in 1 patient, suggesting transient heart injury [9]. It"/>
  <result pre="18 patients (4.9%) and atrial fibrillation in 1 patient, suggesting" exact="transient" post="heart injury [9]. It was shown that in addition"/>
  <result pre="patients (4.9%) and atrial fibrillation in 1 patient, suggesting transient" exact="heart" post="injury [9]. It was shown that in addition to"/>
  <result pre="sinus tachycardia, SARS-CoV can also cause supraventricular arrhythmia, ventricular arrhythmia," exact="first-degree atrioventricular block," post="and ST-T segment changes [10]. Similarly, 23 (16.7%) of"/>
  <result pre="tachycardia, SARS-CoV can also cause supraventricular arrhythmia, ventricular arrhythmia, first-degree" exact="atrioventricular block," post="and ST-T segment changes [10]. Similarly, 23 (16.7%) of"/>
  <result pre="changes [10]. Similarly, 23 (16.7%) of 138 COVID-19 patients had" exact="arrhythmia" post="[8]. Furthermore, Guan et al. found that severe and"/>
  <result pre="tachycardia, which may be associated with exacerbation [11]. Some coronavirus" exact="infections" post="may seriously affect the heart. For instance, in rabbits,"/>
  <result pre="affect the heart. For instance, in rabbits, coronavirus may induce" exact="cardiomyopathy" post="that may result in cardiac chamber dilatation and impairment"/>
  <result pre="[12]. Chen et al. found that patients, even without underlying" exact="cardiovascular" post="diseases, can also suffer from severe heart failure in"/>
  <result pre="even without underlying cardiovascular diseases, can also suffer from severe" exact="heart" post="failure in the wake of SARS-CoV-2 infection and eventually"/>
  <result pre="suffer from severe heart failure in the wake of SARS-CoV-2" exact="infection" post="and eventually die of sudden cardiac death [7]. Likewise,"/>
  <result pre="[7]. Likewise, Hu et al. reported a case of coronavirus" exact="infection" post="presenting fulminant myocarditis [13], and Gnecchi et al. reported"/>
  <result pre="et al. reported a case of coronavirus infection presenting fulminant" exact="myocarditis" post="[13], and Gnecchi et al. reported a case of"/>
  <result pre="myocarditis [13], and Gnecchi et al. reported a case of" exact="acute" post="myocarditis in a 16-year-old boy positive for SARS-CoV-2 [14]."/>
  <result pre="[13], and Gnecchi et al. reported a case of acute" exact="myocarditis" post="in a 16-year-old boy positive for SARS-CoV-2 [14]. The"/>
  <result pre="16-year-old boy positive for SARS-CoV-2 [14]. The patient, complaining of" exact="chest" post="pain, did not have any of the signs or"/>
  <result pre="or symptoms typically reported in COVID-19, indicating the possibility that" exact="cardiovascular" post="involvement may exclusively be due to COVID-19 and not"/>
  <result pre="Betacoronavirus genus, electrocardiographic changes and troponin elevation may signal underlying" exact="heart" post="injury, and echocardiography frequently demonstrates subclinical left ventricular diastolic"/>
  <result pre="demonstrates subclinical left ventricular diastolic impairment in COVID-19 patients. 2.2" exact="Chronic" post="cardiac damage The clinical effects of pneumonia have been"/>
  <result pre="COVID-19 patients. 2.2 Chronic cardiac damage The clinical effects of" exact="pneumonia" post="have been associated with an increased risk of cardiovascular"/>
  <result pre="of pneumonia have been associated with an increased risk of" exact="cardiovascular disease" post="up to a 10-year follow-up [15]. Long-term follow-up data"/>
  <result pre="pneumonia have been associated with an increased risk of cardiovascular" exact="disease" post="up to a 10-year follow-up [15]. Long-term follow-up data"/>
  <result pre="patients showed that 68% of survivors had hyperlipidemia, 44% had" exact="cardiovascular" post="system abnormalities and 60% had glucose metabolism disorders [16]."/>
  <result pre="lysophosphatidylcholine levels. However, the mechanisms by which SARS-CoV leads to" exact="dyslipidemia" post="and long-term cardiovascular damage are still unclear. It is"/>
  <result pre="the mechanisms by which SARS-CoV leads to dyslipidemia and long-term" exact="cardiovascular" post="damage are still unclear. It is worth paying attention"/>
  <result pre="unclear. It is worth paying attention to whether SARS-CoV-2 causes" exact="chronic" post="damage to the cardiovascular system. Recently, Puntmann et al."/>
  <result pre="paying attention to whether SARS-CoV-2 causes chronic damage to the" exact="cardiovascular" post="system. Recently, Puntmann et al. demonstrated that patients who"/>
  <result pre="that the virus may have a long-term effect on the" exact="heart" post="[17,18]. 2.3 SARS-CoV-2 infection with underlying cardiovascular disease Some"/>
  <result pre="have a long-term effect on the heart [17,18]. 2.3 SARS-CoV-2" exact="infection" post="with underlying cardiovascular disease Some SARS-CoV-2 patients have chronic"/>
  <result pre="effect on the heart [17,18]. 2.3 SARS-CoV-2 infection with underlying" exact="cardiovascular disease" post="Some SARS-CoV-2 patients have chronic underlying diseases, especially cardiovascular"/>
  <result pre="on the heart [17,18]. 2.3 SARS-CoV-2 infection with underlying cardiovascular" exact="disease" post="Some SARS-CoV-2 patients have chronic underlying diseases, especially cardiovascular"/>
  <result pre="SARS-CoV-2 infection with underlying cardiovascular disease Some SARS-CoV-2 patients have" exact="chronic" post="underlying diseases, especially cardiovascular disease and diabetes, and these"/>
  <result pre="cardiovascular disease Some SARS-CoV-2 patients have chronic underlying diseases, especially" exact="cardiovascular disease" post="and diabetes, and these patients are more susceptible to"/>
  <result pre="disease Some SARS-CoV-2 patients have chronic underlying diseases, especially cardiovascular" exact="disease" post="and diabetes, and these patients are more susceptible to"/>
  <result pre="and these patients are more susceptible to severe conditions after" exact="infection" post="[8]. The Chinese Centers for Disease Control and Prevention"/>
  <result pre="to severe conditions after infection [8]. The Chinese Centers for" exact="Disease" post="Control and Prevention released a report of more than"/>
  <result pre="with overall mortality rates of approximately 10.5% in patients with" exact="cardiovascular disease" post="and 6.0% in patients with hypertension [19]. An analysis"/>
  <result pre="overall mortality rates of approximately 10.5% in patients with cardiovascular" exact="disease" post="and 6.0% in patients with hypertension [19]. An analysis"/>
  <result pre="in patients with cardiovascular disease and 6.0% in patients with" exact="hypertension" post="[19]. An analysis of 1099 clinical patients suggested that"/>
  <result pre="of 1099 clinical patients suggested that COVID-19 patients with previous" exact="cardiovascular" post="diseases, such as hypertension and coronary heart disease, were"/>
  <result pre="suggested that COVID-19 patients with previous cardiovascular diseases, such as" exact="hypertension" post="and coronary heart disease, were at higher risk for"/>
  <result pre="COVID-19 patients with previous cardiovascular diseases, such as hypertension and" exact="coronary heart disease," post="were at higher risk for cardiovascular system damage or"/>
  <result pre="patients with previous cardiovascular diseases, such as hypertension and coronary" exact="heart" post="disease, were at higher risk for cardiovascular system damage"/>
  <result pre="hypertension and coronary heart disease, were at higher risk for" exact="cardiovascular" post="system damage or mortality [11]. Chronic cardiovascular diseases reduce"/>
  <result pre="at higher risk for cardiovascular system damage or mortality [11]." exact="Chronic" post="cardiovascular diseases reduce the natural cardiac reserve and impair"/>
  <result pre="higher risk for cardiovascular system damage or mortality [11]. Chronic" exact="cardiovascular" post="diseases reduce the natural cardiac reserve and impair the"/>
  <result pre="pneumonia. As a result, these patients are more susceptible to" exact="acute" post="cardiovascular events after infection. For example, the systemic inflammatory"/>
  <result pre="As a result, these patients are more susceptible to acute" exact="cardiovascular" post="events after infection. For example, the systemic inflammatory response"/>
  <result pre="susceptible to acute cardiovascular events after infection. For example, the" exact="systemic" post="inflammatory response and its procoagulant effects may lead to"/>
  <result pre="response and its procoagulant effects may lead to plaque rupture," exact="thrombosis" post="and myocardial infarction in patients with coronary heart disease"/>
  <result pre="its procoagulant effects may lead to plaque rupture, thrombosis and" exact="myocardial infarction" post="in patients with coronary heart disease [20]. In Shanghai,"/>
  <result pre="to plaque rupture, thrombosis and myocardial infarction in patients with" exact="coronary heart disease" post="[20]. In Shanghai, the first death related to SARS-CoV-2"/>
  <result pre="plaque rupture, thrombosis and myocardial infarction in patients with coronary" exact="heart" post="disease [20]. In Shanghai, the first death related to"/>
  <result pre="rupture, thrombosis and myocardial infarction in patients with coronary heart" exact="disease" post="[20]. In Shanghai, the first death related to SARS-CoV-2"/>
  <result pre="disease [20]. In Shanghai, the first death related to SARS-CoV-2" exact="pneumonia" post="was an 88-year-old patient with severe hypertension and cardiac"/>
  <result pre="related to SARS-CoV-2 pneumonia was an 88-year-old patient with severe" exact="hypertension" post="and cardiac insufficiency. Further analysis showed that the SARS-CoV-2"/>
  <result pre="hypertension and cardiac insufficiency. Further analysis showed that the SARS-CoV-2" exact="infection" post="only induced heart failure and systemic multiorgan dysfunction in"/>
  <result pre="insufficiency. Further analysis showed that the SARS-CoV-2 infection only induced" exact="heart" post="failure and systemic multiorgan dysfunction in the patient [21]."/>
  <result pre="showed that the SARS-CoV-2 infection only induced heart failure and" exact="systemic" post="multiorgan dysfunction in the patient [21]. 3 SARS-CoV-2 possible"/>
  <result pre="dysfunction in the patient [21]. 3 SARS-CoV-2 possible mechanisms for" exact="heart" post="damage 3.1 Direct cardiac infection by SARS-CoV-2 Some COVID-19"/>
  <result pre="3 SARS-CoV-2 possible mechanisms for heart damage 3.1 Direct cardiac" exact="infection" post="by SARS-CoV-2 Some COVID-19 patients have chest pain and"/>
  <result pre="3.1 Direct cardiac infection by SARS-CoV-2 Some COVID-19 patients have" exact="chest" post="pain and other cardiovascular symptoms as the main symptoms,"/>
  <result pre="by SARS-CoV-2 Some COVID-19 patients have chest pain and other" exact="cardiovascular" post="symptoms as the main symptoms, and the serological markers"/>
  <result pre="The virus mainly exists in endothelial cells, which may affect" exact="heart" post="microcirculation and lead to abnormal myocardial zymograms. However, we"/>
  <result pre="the patients who underwent autopsy did not show symptoms of" exact="myocarditis" post="during the illness. Xu et al. discovered that compared"/>
  <result pre="internalized into alveolar cells [2]. Moreover, one study found that" exact="epithelial" post="cells infected with SARS-CoV-2 can lead to an increase"/>
  <result pre="is likely to attack cells of the myocardium [27]. The" exact="viral" post="load in vivo increases and lasts for more than"/>
  <result pre="suggesting that the virus could directly attack cardiomyocytes and cause" exact="viral" post="myocarditis [28]. However, additional pathological evidence is needed to"/>
  <result pre="that the virus could directly attack cardiomyocytes and cause viral" exact="myocarditis" post="[28]. However, additional pathological evidence is needed to confirm"/>
  <result pre="pathological evidence is needed to confirm the direction of cardiomyocyte" exact="infection" post="by SARS-CoV-2. 3.2 Downregulation of ACE2 in cardiac tissues"/>
  <result pre="a member of the zinc metalloprotease family and is a" exact="type I" post="membrane protein encoded by a gene on the X"/>
  <result pre="negative regulator of RAS and provides protective effects for the" exact="cardiovascular" post="system (Fig. 1 ). (See Table 1 .) Fig."/>
  <result pre="and ACE effects. Table 1 Treatment plan of corona virus" exact="disease" post="2019 (COVID-19). Table 1 Patient Clinical types Clinical manifestations"/>
  <result pre="appropriate criteria of The Diagnosis and Treatment plan of Corona" exact="Virus Disease" post="2019 (Tentative Seventh Edition) [46] General treatment:1.Support therapy2.Monitoring life"/>
  <result pre="criteria of The Diagnosis and Treatment plan of Corona Virus" exact="Disease" post="2019 (Tentative Seventh Edition) [46] General treatment:1.Support therapy2.Monitoring life"/>
  <result pre="plan of Corona Virus Disease 2019 (Tentative Seventh Edition) [46]" exact="General" post="treatment:1.Support therapy2.Monitoring life signs3.Oxygen therapy4. Antiviral drugs5.Antibiotics when necessary"/>
  <result pre="General treatment:1.Support therapy2.Monitoring life signs3.Oxygen therapy4. Antiviral drugs5.Antibiotics when necessary" exact="Severe" post="or critical COVID-19 patients 1.General treatment2.Respiratory support: mechanical ventilation,"/>
  <result pre="patients 1.General treatment2.Respiratory support: mechanical ventilation, extracorporeal membrane oxygenation(ECMO) for" exact="acute" post="respiratory distress syndrome patients Patient with renal failure symptoms"/>
  <result pre="1.General treatment2.Respiratory support: mechanical ventilation, extracorporeal membrane oxygenation(ECMO) for acute" exact="respiratory" post="distress syndrome patients Patient with renal failure symptoms 1.General"/>
  <result pre="support: mechanical ventilation, extracorporeal membrane oxygenation(ECMO) for acute respiratory distress" exact="syndrome" post="patients Patient with renal failure symptoms 1.General and symptomatic"/>
  <result pre="membrane oxygenation(ECMO) for acute respiratory distress syndrome patients Patient with" exact="renal failure" post="symptoms 1.General and symptomatic treatment 2.Etiological therapy 3.Continuous renal"/>
  <result pre="distress syndrome patients Patient with renal failure symptoms 1.General and" exact="symptomatic" post="treatment 2.Etiological therapy 3.Continuous renal replacement therapy Patient with"/>
  <result pre="symptomatic treatment 2.Etiological therapy 3.Continuous renal replacement therapy Patient with" exact="disease" post="progressed quickly 1.General and symptomatic treatment 2.Rehabilitee plasma therapy"/>
  <result pre="renal replacement therapy Patient with disease progressed quickly 1.General and" exact="symptomatic" post="treatment 2.Rehabilitee plasma therapy Patient with cytokine storm 1.General"/>
  <result pre="treatment 2.Rehabilitee plasma therapy Patient with cytokine storm 1.General and" exact="symptomatic" post="treatment 2.Blood purification: plasma exchange, adsorption, perfusion i.e. Patient"/>
  <result pre="i.e. Patient with the increase of serum IL-6 1.General and" exact="symptomatic" post="treatment 2.Immunotherapy: trastuzumab (IL-6 mAb) Patient with excessive inflammatory"/>
  <result pre="2.Immunotherapy: trastuzumab (IL-6 mAb) Patient with excessive inflammatory response, severe" exact="respiratory" post="distress and so on 1.General and symptomatic treatment 2.Glucocorticoid"/>
  <result pre="inflammatory response, severe respiratory distress and so on 1.General and" exact="symptomatic" post="treatment 2.Glucocorticoid 3.Xuebijing injection (a traditional Chinese medicine): intravenous"/>
  <result pre="Chinese medicine): intravenous 100â€¯ml/day, twice a day 4.Microecological preparation prevents" exact="secondary" post="bacterial infection COVID-19 patient complicated with cardiovascular system injury"/>
  <result pre="medicine): intravenous 100â€¯ml/day, twice a day 4.Microecological preparation prevents secondary" exact="bacterial infection" post="COVID-19 patient complicated with cardiovascular system injury COVID-19 patient"/>
  <result pre="intravenous 100â€¯ml/day, twice a day 4.Microecological preparation prevents secondary bacterial" exact="infection" post="COVID-19 patient complicated with cardiovascular system injury COVID-19 patient"/>
  <result pre="4.Microecological preparation prevents secondary bacterial infection COVID-19 patient complicated with" exact="cardiovascular" post="system injury COVID-19 patient with acute cardiac injury [75]"/>
  <result pre="COVID-19 patient complicated with cardiovascular system injury COVID-19 patient with" exact="acute" post="cardiac injury [75] The increase of myocardial enzyme spectrum"/>
  <result pre="1.Medications to protect myocardium and improve cardiac function: Co-enzyme Q," exact="Vitamin C," post="sodium creatine phosphate COVID-19 patient with arrhythmia Electrocardiogram abnormal,"/>
  <result pre="Co-enzyme Q, Vitamin C, sodium creatine phosphate COVID-19 patient with" exact="arrhythmia" post="Electrocardiogram abnormal, clinic symptoms such as palpitation, chest stuffiness"/>
  <result pre="patient with arrhythmia Electrocardiogram abnormal, clinic symptoms such as palpitation," exact="chest" post="stuffiness 1.Antiarrhythmics 2.Anticoagulant 3.Intervention therapy COVID-19 patient with heart"/>
  <result pre="palpitation, chest stuffiness 1.Antiarrhythmics 2.Anticoagulant 3.Intervention therapy COVID-19 patient with" exact="heart" post="failure [73] Patient with the increase of BNP,or the"/>
  <result pre="1.Etiological therapy 2.Anti-heart failure 3.EOMO when necessary COVID-19 patient with" exact="acute" post="coronary syndrome [73] Acute chest pain,the changes of cTnI,"/>
  <result pre="2.Anti-heart failure 3.EOMO when necessary COVID-19 patient with acute coronary" exact="syndrome" post="[73] Acute chest pain,the changes of cTnI, electrocardiogram abnormal."/>
  <result pre="3.EOMO when necessary COVID-19 patient with acute coronary syndrome [73]" exact="Acute" post="chest pain,the changes of cTnI, electrocardiogram abnormal. i.e. 1.Thrombolysis"/>
  <result pre="when necessary COVID-19 patient with acute coronary syndrome [73] Acute" exact="chest" post="pain,the changes of cTnI, electrocardiogram abnormal. i.e. 1.Thrombolysis 2.Percutaneous"/>
  <result pre="i.e. 1.Thrombolysis 2.Percutaneous coronary intervention (PCI) when necessary COVID-19, Corona" exact="Virus Disease" post="2019; ECMO, extracorporeal membrane oxygenation; IL-6 mAb, interleukin 6"/>
  <result pre="1.Thrombolysis 2.Percutaneous coronary intervention (PCI) when necessary COVID-19, Corona Virus" exact="Disease" post="2019; ECMO, extracorporeal membrane oxygenation; IL-6 mAb, interleukin 6"/>
  <result pre="6 monoclonal antibody; cTnI, cardiac troponin I, which can reflect" exact="myocardial infarction;" post="BNP, brain natriuretic peptide, a marker of heart failure."/>
  <result pre="cTnI, cardiac troponin I, which can reflect myocardial infarction; BNP," exact="brain" post="natriuretic peptide, a marker of heart failure. Crackower et"/>
  <result pre="reflect myocardial infarction; BNP, brain natriuretic peptide, a marker of" exact="heart" post="failure. Crackower et al. showed that ACE2 knockout has"/>
  <result pre="Ang II, which could accelerate the occurrence and development of" exact="cardiovascular" post="diseases. On the other hand, studies have shown that"/>
  <result pre="ACE, angiotensin converting enzyme; ACE2ï¼Œangiotensin converting enzyme 2; AT 1Rï¼Œangiotensin" exact="type I" post="receptor. B1 receptor, Bradykinin 1 receptor, B2 receptorï¼ŒBradykinin 2"/>
  <result pre="receptor. â‘ The predominant physiological function of ACE is in" exact="cardiovascular" post="homeostasis through hydrolyzing Ang I to produce the potent"/>
  <result pre="of mediating the production of interleukin-6. 3.3 Cytokine storms and" exact="autoimmune" post="response Many severe patients among the first confirmed SARS-CoV-2"/>
  <result pre="rapid production of a large amount of various cytokines, including" exact="tumor" post="necrosis factor-Î± (TNF-Î±), interleukin 1 (IL-1), interleukin 6 (IL-6),"/>
  <result pre="fluids following microbial infection. It is an important cause of" exact="acute" post="lung injury, acute respiratory distress syndrome (ARDS) and multiorgan"/>
  <result pre="infection. It is an important cause of acute lung injury," exact="acute" post="respiratory distress syndrome (ARDS) and multiorgan disorders in patients"/>
  <result pre="It is an important cause of acute lung injury, acute" exact="respiratory" post="distress syndrome (ARDS) and multiorgan disorders in patients with"/>
  <result pre="an important cause of acute lung injury, acute respiratory distress" exact="syndrome" post="(ARDS) and multiorgan disorders in patients with viral infections"/>
  <result pre="respiratory distress syndrome (ARDS) and multiorgan disorders in patients with" exact="viral" post="infections [33]. As mentioned above, ACE2 has an inhibitory"/>
  <result pre="distress syndrome (ARDS) and multiorgan disorders in patients with viral" exact="infections" post="[33]. As mentioned above, ACE2 has an inhibitory action"/>
  <result pre="Ang II levels in COVID-19 patients are closely correlated with" exact="viral" post="titer and lung injury, suggesting that SARS-CoV-2 may lead"/>
  <result pre="titer and lung injury, suggesting that SARS-CoV-2 may lead to" exact="acute" post="lung injury due to an imbalance in the renin-angiotensin"/>
  <result pre="the inflammatory storm. Early studies showed that in SARS patients," exact="elevated serum" post="pro-inflammatory cytokines, including IL-1Î², IL-6, IL-12, IFN-Î³, interferon-inducible protein"/>
  <result pre="including IL-1Î², IL-6, IL-12, IFN-Î³, interferon-inducible protein 10 (IP10), and" exact="monocyte" post="chemoattractant protein 1 (MCP1), were related to pulmonary inflammation"/>
  <result pre="(IP10), and monocyte chemoattractant protein 1 (MCP1), were related to" exact="pulmonary" post="inflammation and lung injury [34]. Similarly, Huang et al."/>
  <result pre="IFN-Î³, IP10, and MCP1, which may lead to T helper" exact="type 1" post="(Th1)/Th2 imbalance and cause T cell-mediated immune injury [6]."/>
  <result pre="cytokine storms are positively correlated with the severity of the" exact="disease" post="[6]. One retrospective study found that increases in COVID-19"/>
  <result pre="decrease in lymphocyte counts and CD4/CD8 ratios, suggesting that SARS-CoV-2" exact="infections" post="may lead to heart damage through excessive inflammatory responses"/>
  <result pre="and CD4/CD8 ratios, suggesting that SARS-CoV-2 infections may lead to" exact="heart" post="damage through excessive inflammatory responses [36]. Previous studies reported"/>
  <result pre="interleukin 8 (IL-8) and TNF-Î± can promote coagulation and even" exact="thrombosis" post="via multiple pathways, increasing the risk of thromboembolism [37]."/>
  <result pre="mechanisms of myocardial injury. 3.4 Other mechanisms Hypoxemia caused by" exact="viral infection" post="is another important mechanism of cardiac damage since it"/>
  <result pre="of myocardial injury. 3.4 Other mechanisms Hypoxemia caused by viral" exact="infection" post="is another important mechanism of cardiac damage since it"/>
  <result pre="stress. Acidosis and the generation of oxygen free radicals during" exact="hypoxia" post="and hypoxia-reperfusion can aggravate myocardial injury, while hypoxia can"/>
  <result pre="radicals during hypoxia and hypoxia-reperfusion can aggravate myocardial injury, while" exact="hypoxia" post="can also induce inflammatory responses, thereby further aggravating cardiac"/>
  <result pre="treatment of COVID-19. The Diagnosis and Treatment Plan of Coronavirus" exact="Disease" post="2019 (Tentative seventh version) recommends the use of lopinavir"/>
  <result pre="be used in combination with statins or for patients with" exact="coronary heart disease" post="[41]. Chloroquine can cause cardiac arrhythmias and even cardiac"/>
  <result pre="used in combination with statins or for patients with coronary" exact="heart" post="disease [41]. Chloroquine can cause cardiac arrhythmias and even"/>
  <result pre="in combination with statins or for patients with coronary heart" exact="disease" post="[41]. Chloroquine can cause cardiac arrhythmias and even cardiac"/>
  <result pre="heart disease [41]. Chloroquine can cause cardiac arrhythmias and even" exact="cardiac arrest," post="the most serious adverse reaction [42]. For COVID-19 patients,"/>
  <result pre="In addition, Arbidol is associated with an increase in the" exact="heart" post="failure rate when used in combination with drugs such"/>
  <result pre="quinolones [44]. Interferons may affect the cardiac conduction system, causing" exact="cardiac arrhythmia" post="as well as local myocardial ischemia and cardiomyopathy [45]."/>
  <result pre="[44]. Interferons may affect the cardiac conduction system, causing cardiac" exact="arrhythmia" post="as well as local myocardial ischemia and cardiomyopathy [45]."/>
  <result pre="cardiac conduction system, causing cardiac arrhythmia as well as local" exact="myocardial ischemia" post="and cardiomyopathy [45]. In addition, for COVID-19 patients, excessive"/>
  <result pre="conduction system, causing cardiac arrhythmia as well as local myocardial" exact="ischemia" post="and cardiomyopathy [45]. In addition, for COVID-19 patients, excessive"/>
  <result pre="causing cardiac arrhythmia as well as local myocardial ischemia and" exact="cardiomyopathy" post="[45]. In addition, for COVID-19 patients, excessive anxiety, tension,"/>
  <result pre="function and may even cause stress cardiomyopathy. 4 Treatment of" exact="cardiovascular" post="injury associated with SARS-CoV-2 infection 4.1 Antiviral therapy The"/>
  <result pre="stress cardiomyopathy. 4 Treatment of cardiovascular injury associated with SARS-CoV-2" exact="infection" post="4.1 Antiviral therapy The Diagnosis and Treatment Plan of"/>
  <result pre="Efficacy of Favipiravir in the Treatment of Patients with Coronavirus" exact="Disease" post="2019 (COVID-19)â€� (Registration Number: ChiCTR2000029600) suggested that favipiravir may"/>
  <result pre="lopinavir/ritonavir treatment is no better than standard care in hospitalized" exact="adult" post="patients with severe COVID-19 [50]. 4.2 ACE2 as a"/>
  <result pre="ACE2 as a potential target during the treatment of SARS-CoV-2" exact="infection" post="SARS-CoV-2 mainly invades alveolar epithelial cells via ACE2 and"/>
  <result pre="during the treatment of SARS-CoV-2 infection SARS-CoV-2 mainly invades alveolar" exact="epithelial" post="cells via ACE2 and causes pulmonary inflammation. However, as"/>
  <result pre="SARS-CoV-2 mainly invades alveolar epithelial cells via ACE2 and causes" exact="pulmonary" post="inflammation. However, as the number of infections has increased,"/>
  <result pre="ACE2 and causes pulmonary inflammation. However, as the number of" exact="infections" post="has increased, some patients have presented with virus-associated cardiovascular"/>
  <result pre="of infections has increased, some patients have presented with virus-associated" exact="cardiovascular" post="injury, which may result from direct myocardial injury via"/>
  <result pre="SARS-CoV-2, suppressing ACE, and using recombinant human ACE2 protein for" exact="pulmonary" post="protection. 4.2.1 Blocking the binding between SARS-CoV-2 and ACE2"/>
  <result pre="or changing its configuration may be potential approaches. Chloroquine inhibits" exact="viral infection" post="by increasing the pH of the viral inclusion bodies"/>
  <result pre="changing its configuration may be potential approaches. Chloroquine inhibits viral" exact="infection" post="by increasing the pH of the viral inclusion bodies"/>
  <result pre="Chloroquine inhibits viral infection by increasing the pH of the" exact="viral" post="inclusion bodies required for virus-cell fusion and interfering with"/>
  <result pre="scheduled for large clinical trials [55]. It was suggested that" exact="type II" post="transmembrane serine proteases (TMSPSS2) can activate SARS-CoV-2â€¯S proteins to"/>
  <result pre="trial phase, with 6 in phase III, including a nonreplicating" exact="viral" post="vector (ChAdOx1â€&quot;5) from the University of Oxford (ISRCTN89951424), an"/>
  <result pre="may result in overactivation of the AT 1 receptor and" exact="acute" post="lung injury [57]. Decreased ACE2 combined with elevated Ang"/>
  <result pre="In animal studies, the administration of enalapril in mice with" exact="acute" post="lung injury quickly reduced Ang II levels [58], while"/>
  <result pre="(IL-4) levels, thereby regulating the Th1/Th2 balance [59] and reducing" exact="pulmonary" post="inflammation and lung injury. A retrospective study showed that"/>
  <result pre="dilate vessels and reduce blood pressure but may also increase" exact="vascular" post="permeability and aggravate pulmonary edema. Bradykinin also mediates IL-6"/>
  <result pre="blood pressure but may also increase vascular permeability and aggravate" exact="pulmonary" post="edema. Bradykinin also mediates IL-6 production via the B2R/Erk"/>
  <result pre="inflammation. Therefore, Liu et al. recommended that COVID-19 patients with" exact="hypertension" post="discontinue the antihypertensive ACEIs and ARBs (if applicable) and"/>
  <result pre="to calcium channel blockers (CCBs). However, the European Society of" exact="Hypertension" post="(ESH) emphasized that there is no evidence that ACEIs"/>
  <result pre="that ACEIs and ARBs can increase the risk of SARS-CoV-2" exact="infection" post="or cause deterioration of COVID-19 patients [62], so ACEIs"/>
  <result pre="should not be discontinued easily for COVID-19 patients with pre-existing" exact="cardiovascular disease." post="For stable patients, the use of ACEIs and ARBs"/>
  <result pre="discontinued easily for COVID-19 patients with pre-existing cardiovascular disease. For" exact="stable" post="patients, the use of ACEIs and ARBs should be"/>
  <result pre="have shown that treating ACE2-knockout mice with rhuACE2 injections reduced" exact="acute" post="lung injury resulting from acid aspiration or sepsis and"/>
  <result pre="lung injury resulting from acid aspiration or sepsis and improved" exact="pulmonary" post="edema [57]. In a phase II clinical study, the"/>
  <result pre="the ACE2/ACE balance in the lungs and help to treat" exact="acute" post="lung injury [64]. Recently, Monteil et al. found that"/>
  <result pre="recombinant soluble ACE2 can prevent SARS-CoV-2 from infecting engineered human" exact="blood vessels" post="and kidneys [65]. 4.3 Treatment of cytokine storms associated"/>
  <result pre="kidneys [65]. 4.3 Treatment of cytokine storms associated with SARS-CoV-2" exact="infection" post="As mentioned previously, SARS-CoV-2 infection could induce overactivation of"/>
  <result pre="cytokine storms associated with SARS-CoV-2 infection As mentioned previously, SARS-CoV-2" exact="infection" post="could induce overactivation of the immune system, resulting in"/>
  <result pre="the immune system, resulting in cytokine storms, multiple organ dysfunction" exact="syndrome" post="(MODS), and even death. Therefore, the combination of blocking"/>
  <result pre="protecting organ function is a promising approach to treat SARS-CoV-2" exact="infection" post="and reduce mortality. Currently, most targeted drugs for COVID-19"/>
  <result pre="for COVID-19 are still being tested in preclinical studies, and" exact="symptomatic" post="treatment remains the primary therapy. It is essential to"/>
  <result pre="being tested in preclinical studies, and symptomatic treatment remains the" exact="primary" post="therapy. It is essential to promptly and effectively block"/>
  <result pre="the following treatments for cytokine storms: antishock therapy, supportive and" exact="symptomatic" post="treatment, proper steroid treatment at an appropriate dose level,"/>
  <result pre="neutralizing antibodies [66]. The Diagnosis and Treatment plan of Corona" exact="Virus Disease" post="2019 (Tentative Seventh Edition) recommends that patients with an"/>
  <result pre="antibodies [66]. The Diagnosis and Treatment plan of Corona Virus" exact="Disease" post="2019 (Tentative Seventh Edition) recommends that patients with an"/>
  <result pre="It should be noted that high-dose steroid therapy may delay" exact="viral" post="clearance. Moreover, blood purification therapy may be considered if"/>
  <result pre="may be used to treat cytokine storms associated with SARS-CoV-2" exact="infection" post="[68]. Zhou et al. found that granulocyte-macrophage colony stimulating"/>
  <result pre="Trial Registry [70]. The Diagnosis and Treatment Plan of Corona" exact="Virus Disease" post="(Tentative Seventh Edition) recommends the use of plasma therapy"/>
  <result pre="Registry [70]. The Diagnosis and Treatment Plan of Corona Virus" exact="Disease" post="(Tentative Seventh Edition) recommends the use of plasma therapy"/>
  <result pre="methods for treating and preventing COVID-19. 4.4 Treatment of SARS-CoV-2" exact="infection" post="with underlying cardiovascular diseases Current data show that all"/>
  <result pre="and preventing COVID-19. 4.4 Treatment of SARS-CoV-2 infection with underlying" exact="cardiovascular" post="diseases Current data show that all age groups are"/>
  <result pre="[73]. Fifty percent of COVID-19 patients had complications, of which" exact="hypertension" post="was the most common comorbidity, followed by diabetes and"/>
  <result pre="of which hypertension was the most common comorbidity, followed by" exact="diabetes" post="and coronary heart disease, that led to high mortality"/>
  <result pre="hypertension was the most common comorbidity, followed by diabetes and" exact="coronary heart disease," post="that led to high mortality [38]. Therefore, COVID-19 patients"/>
  <result pre="was the most common comorbidity, followed by diabetes and coronary" exact="heart" post="disease, that led to high mortality [38]. Therefore, COVID-19"/>
  <result pre="led to high mortality [38]. Therefore, COVID-19 patients with pre-existing" exact="cardiovascular disease" post="should be closely monitored for any symptoms and signs"/>
  <result pre="to high mortality [38]. Therefore, COVID-19 patients with pre-existing cardiovascular" exact="disease" post="should be closely monitored for any symptoms and signs"/>
  <result pre="should be closely monitored for any symptoms and signs of" exact="cardiovascular" post="dysfunction. Recently, the American College of Cardiology (ACC) released"/>
  <result pre="for any symptoms and signs of cardiovascular dysfunction. Recently, the" exact="American" post="College of Cardiology (ACC) released a clinical bulletin [74]"/>
  <result pre="statins, Î²-blockers, ACE inhibitors, aspirin) and provides additional protection for" exact="cardiovascular" post="patients should be administered. When acute myocardial injury occurs,"/>
  <result pre="provides additional protection for cardiovascular patients should be administered. When" exact="acute" post="myocardial injury occurs, medication to improve myocardial energy metabolism"/>
  <result pre="metabolism can significantly protect and improve cardiac function, and when" exact="heart" post="failure occurs, etiological treatment is the optimal choice. In"/>
  <result pre="as early as possible. Moreover, for COVID-19 patients comorbid with" exact="chronic" post="underlying cardiovascular disease, the primary cardiovascular disease must be"/>
  <result pre="as possible. Moreover, for COVID-19 patients comorbid with chronic underlying" exact="cardiovascular disease," post="the primary cardiovascular disease must be managed, and organ"/>
  <result pre="for COVID-19 patients comorbid with chronic underlying cardiovascular disease, the" exact="primary" post="cardiovascular disease must be managed, and organ protection and"/>
  <result pre="COVID-19 patients comorbid with chronic underlying cardiovascular disease, the primary" exact="cardiovascular disease" post="must be managed, and organ protection and homeostasis maintenance"/>
  <result pre="patients comorbid with chronic underlying cardiovascular disease, the primary cardiovascular" exact="disease" post="must be managed, and organ protection and homeostasis maintenance"/>
  <result pre="maintenance must be ensured during antiviral therapy. If a critical" exact="cardiovascular" post="condition occurs in a COVID-19 patient, the treatment principles"/>
  <result pre="a COVID-19 patient, the treatment principles include treatment of the" exact="viral infection" post="first, followed by risk assessment, conservative treatment (preferred), and"/>
  <result pre="COVID-19 patient, the treatment principles include treatment of the viral" exact="infection" post="first, followed by risk assessment, conservative treatment (preferred), and"/>
  <result pre="(preferred), and self-protection. Thrombolysis is preferred for patients with non-ST-elevation" exact="myocardial infarction" post="(NSTEMI) or ST-elevation myocardial infarction (STEMI) without relevant contraindications;"/>
  <result pre="preferred for patients with non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation" exact="myocardial infarction" post="(STEMI) without relevant contraindications; emergency percutaneous coronary intervention (PCI)"/>
  <result pre="(PCI) may be performed under close monitoring in patients with" exact="acute" post="STEMI with hemodynamic instability and patients with life-threatening NSTEMI"/>
  <result pre="frequently and ventilating rooms regularly. After all, 86% of all" exact="infections" post="were undocumented before the 23 January 2020 travel restrictions,"/>
  <result pre="the prognosis of patients. 6 Conclusion The outbreak of SARS-CoV-2" exact="infection" post="has been defined as a pandemic that is seriously"/>
  <result pre="can spread through many transmission routes. Early reports show that" exact="cardiovascular" post="injury in the wake of viral epidemics is not"/>
  <result pre="Early reports show that cardiovascular injury in the wake of" exact="viral" post="epidemics is not uncommon. In addition, patients with chronic"/>
  <result pre="of viral epidemics is not uncommon. In addition, patients with" exact="chronic" post="cardiovascular disease are at an increased risk of acute"/>
  <result pre="viral epidemics is not uncommon. In addition, patients with chronic" exact="cardiovascular disease" post="are at an increased risk of acute cardiovascular events"/>
  <result pre="epidemics is not uncommon. In addition, patients with chronic cardiovascular" exact="disease" post="are at an increased risk of acute cardiovascular events"/>
  <result pre="with chronic cardiovascular disease are at an increased risk of" exact="acute" post="cardiovascular events with poor prognosis. To effectively treat COVID-19"/>
  <result pre="chronic cardiovascular disease are at an increased risk of acute" exact="cardiovascular" post="events with poor prognosis. To effectively treat COVID-19 patients,"/>
  <result pre="professionals must be knowledgeable about the prevention and treatment of" exact="infectious diseases" post="while paying attention to the underlying disease and organ"/>
  <result pre="treatment of infectious diseases while paying attention to the underlying" exact="disease" post="and organ protection. We summarized the symptoms and pathogenesis"/>
  <result pre="Group of the International Committee on Taxonomy ofThe species severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat."/>
  <result pre="of the International Committee on Taxonomy ofThe species severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat. Microbiol.5202053654432123347"/>
  <result pre="protein for risk of human transmissionSci. China Life Sci.63202045746032009228 3ZhouP.YangX..WangX.HuB.ZhangL.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet (London, England)3952020507513 8WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.Clinical"/>
  <result pre="8WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJama32320201061106932031570 9YuC.M.WongR.S.WuE.B.KongS.L.WongJ.Cardiovascular complications of severe acute respiratory"/>
  <result pre="novel coronavirus-infected pneumonia in Wuhan, ChinaJama32320201061106932031570 9YuC.M.WongR.S.WuE.B.KongS.L.WongJ.Cardiovascular complications of severe" exact="acute" post="respiratory syndromePostgrad. Med. J.82200614014416461478 10T.g.o.S.o.X.h.CThe clinical characteristics of SARS"/>
  <result pre="coronavirus-infected pneumonia in Wuhan, ChinaJama32320201061106932031570 9YuC.M.WongR.S.WuE.B.KongS.L.WongJ.Cardiovascular complications of severe acute" exact="respiratory" post="syndromePostgrad. Med. J.82200614014416461478 10T.g.o.S.o.X.h.CThe clinical characteristics of SARS and"/>
  <result pre="University of Medical Sciences2420032003361367 11GuanW.NiZ..HuY.LiangW.OuC.HeJ.Clinical characteristics of 2019 novel coronavirus" exact="infection" post="in ChinamedRxiv382202017081720(2020.2002.2006.20020974) 12AlexanderL.SmallJ.EdwardsS.BaricR.An experimental model for dilated cardiomyopathy after"/>
  <result pre="2019 novel coronavirus infection in ChinamedRxiv382202017081720(2020.2002.2006.20020974) 12AlexanderL.SmallJ.EdwardsS.BaricR.An experimental model for" exact="dilated cardiomyopathy" post="after rabbit coronavirus infectionJ. Infect. Dis.16619929789851328411 13HuH.MaF.WeiX.FangY.Coronavirus fulminant myocarditis"/>
  <result pre="novel coronavirus infection in ChinamedRxiv382202017081720(2020.2002.2006.20020974) 12AlexanderL.SmallJ.EdwardsS.BaricR.An experimental model for dilated" exact="cardiomyopathy" post="after rabbit coronavirus infectionJ. Infect. Dis.16619929789851328411 13HuH.MaF.WeiX.FangY.Coronavirus fulminant myocarditis"/>
  <result pre="dilated cardiomyopathy after rabbit coronavirus infectionJ. Infect. Dis.16619929789851328411 13HuH.MaF.WeiX.FangY.Coronavirus fulminant" exact="myocarditis" post="saved with glucocorticoid and human immunoglobulinEur. Heart J.312020ehaa248 14GnecchiM.MorettiF.BassiE.M.LeonardiS.TotaroR.Myocarditis"/>
  <result pre="Dis.16619929789851328411 13HuH.MaF.WeiX.FangY.Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulinEur." exact="Heart" post="J.312020ehaa248 14GnecchiM.MorettiF.BassiE.M.LeonardiS.TotaroR.Myocarditis in a 16-year-old boy positive for SARS-CoV-2Lancet3952020e11632593338"/>
  <result pre="a 16-year-old boy positive for SARS-CoV-2Lancet3952020e11632593338 15Corrales-MedinaV.AlvarezK.WeissfeldL.AngusD.ChirinosJ.ChangC.Association between hospitalization for" exact="pneumonia" post="and subsequent risk of cardiovascular diseaseJAMA313201526427425602997 16WuQ.ZhouL.SunX.YanZ.HuC.WuJ.Altered lipid metabolism"/>
  <result pre="SARS-CoV-2Lancet3952020e11632593338 15Corrales-MedinaV.AlvarezK.WeissfeldL.AngusD.ChirinosJ.ChangC.Association between hospitalization for pneumonia and subsequent risk of" exact="cardiovascular" post="diseaseJAMA313201526427425602997 16WuQ.ZhouL.SunX.YanZ.HuC.WuJ.Altered lipid metabolism in recovered SARS patients twelve"/>
  <result pre="patients identified by magnetic resonance imagingJACC Cardiovasc. Imaging202010.1016/j.jcmg.2020.05.004 18PuntmannV.CarerjM.L.WietersI.FahimM.HoffmannJ.Outcomes of" exact="cardiovascular" post="magnetic resonance imaging in patients recently recovered from coronavirus"/>
  <result pre="cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus" exact="disease" post="2019 (COVID-19)JAMA Cardiol.2020E1E9 19Vital surveillances: the epidemiological characteristics of"/>
  <result pre="2019 novel coronavirus diseases (COVID-19) - ChinaChina CDC Weekly222020113122 20MusherD.AbersM.Corrales-MedinaV.Acute" exact="infection" post="and myocardial infarctionN. Engl. J. Med.380201917117630625066 21S. G, Shanghai"/>
  <result pre="causality of death of the first patient with novel coronavirus" exact="pneumonia" post="is infection in Shanghaihttp://shpeoplecomcn/n2/2020/0126/c134768-33745589html2020 22RongY.LiuY.MaX.ChangB.YangY.Damage to non-pulmonary organs like"/>
  <result pre="death of the first patient with novel coronavirus pneumonia is" exact="infection" post="in Shanghaihttp://shpeoplecomcn/n2/2020/0126/c134768-33745589html2020 22RongY.LiuY.MaX.ChangB.YangY.Damage to non-pulmonary organs like heart and"/>
  <result pre="pneumonia is infection in Shanghaihttp://shpeoplecomcn/n2/2020/0126/c134768-33745589html2020 22RongY.LiuY.MaX.ChangB.YangY.Damage to non-pulmonary organs like" exact="heart" post="and kidney in SARS patients:an analysis of 330 casesAcadmeic"/>
  <result pre="with SARSEur. J. Clin. Investig.39200961862519453650 24ChenL.LiX.ChenM.FengY.XiongC.The ACE2 expression in human" exact="heart" post="indicates new potential mechanism of heart injury among patients"/>
  <result pre="ACE2 expression in human heart indicates new potential mechanism of" exact="heart" post="injury among patients infected with SARS-CoV-2Cardiovasc. Res.202010.1093/cvr/cvaa078 25LindnerD.FitzekA.BrÃ¤uningerH.AleshchevaG.EdlerC.Association of"/>
  <result pre="heart injury among patients infected with SARS-CoV-2Cardiovasc. Res.202010.1093/cvr/cvaa078 25LindnerD.FitzekA.BrÃ¤uningerH.AleshchevaG.EdlerC.Association of" exact="Cardiac" post="Infection with SARS-CoV-2 in confirmed COVID-19 autopsy casesJAMA Cardiol.2020e20355110.1001/jamacardio.2020.3551"/>
  <result pre="injury among patients infected with SARS-CoV-2Cardiovasc. Res.202010.1093/cvr/cvaa078 25LindnerD.FitzekA.BrÃ¤uningerH.AleshchevaG.EdlerC.Association of Cardiac" exact="Infection" post="with SARS-CoV-2 in confirmed COVID-19 autopsy casesJAMA Cardiol.2020e20355110.1001/jamacardio.2020.3551 26ZieglerC.AllonS.NyquistS.MbanoI.MiaoV.TzouanasC.SARS-CoV-2"/>
  <result pre="26ZieglerC.AllonS.NyquistS.MbanoI.MiaoV.TzouanasC.SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway" exact="epithelial" post="cells and is detected in specific cell subsets across"/>
  <result pre="28LiuY.YangY.ZhangC.HuangF.WangF.YuanJ.Clinical and biochemical indexes from 2019-nCoV infected patients linked to" exact="viral" post="loads and lung injurySci. China Life Sci.63202036437432048163 29DonoghueM.HsiehF.BaronasE.GodboutK.GosselinM.StaglianoN.A novel"/>
  <result pre="and atherosclerosisAtherosclerosis22620133822947420 31CrackowerM.A.SaraoR.OuditG.Y.YagilC.KozieradzkiI.ScangaS.E.Angiotensin-converting enzyme 2 is an essential regulator of" exact="heart" post="functionNature417200282282812075344 32SodhiC.P.Wohlford-LenaneC.YamaguchiY.PrindleT.FultonW.B.WangS.Attenuation of pulmonary ACE2 activity impairs inactivation of"/>
  <result pre="2 is an essential regulator of heart functionNature417200282282812075344 32SodhiC.P.Wohlford-LenaneC.YamaguchiY.PrindleT.FultonW.B.WangS.Attenuation of" exact="pulmonary" post="ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R axis and"/>
  <result pre="cytokine stormSemin. Immunopathol.39201754155028555383 34WongC.LamC.WuA.LeeN.ChanI.Plasma inflammatory cytokines and chemokines in severe" exact="acute" post="respiratory syndromeClin. Exp. Immunol.13620049510315030519 35ThevarajanI.NguyenT.H.O.KoutsakosM.DruceJ.CalyL.van de SandtC.E.JiaX.NicholsonS.Breadth of concomitant"/>
  <result pre="stormSemin. Immunopathol.39201754155028555383 34WongC.LamC.WuA.LeeN.ChanI.Plasma inflammatory cytokines and chemokines in severe acute" exact="respiratory" post="syndromeClin. Exp. Immunol.13620049510315030519 35ThevarajanI.NguyenT.H.O.KoutsakosM.DruceJ.CalyL.van de SandtC.E.JiaX.NicholsonS.Breadth of concomitant immune"/>
  <result pre="signs are associated with higher and earlier mortality in coronavirus" exact="disease" post="2019 (COVID-19)medRxiv202010.1101/2020.02.26.20028589(2020.2002.2026.20028589) 37van der PollT.LeviM.Crosstalk between inflammation and coagulation:"/>
  <result pre="Vasc. Pharmacol.10201263263822272914 38ZhouF.YuT.DuR.FanG.LiuY.LiuZ.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="cohort studyLancet (London, England)395202010541062 39XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir. Med.8202042042232085846 40DuanZ.P.ShengL.H.ChenY.LiS.J.Clinical features and mechanisms"/>
  <result pre="studyLancet (London, England)395202010541062 39XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir. Med.8202042042232085846 40DuanZ.P.ShengL.H.ChenY.LiS.J.Clinical features and mechanisms of"/>
  <result pre="respiratory distress syndromeLancet Respir. Med.8202042042232085846 40DuanZ.P.ShengL.H.ChenY.LiS.J.Clinical features and mechanisms of" exact="heart" post="injury in patients suffered from severe acute respiratory syndromeChinese"/>
  <result pre="and mechanisms of heart injury in patients suffered from severe" exact="acute" post="respiratory syndromeChinese J Cardiol312003727730 41WangpatharawanitP.SungkanuparphS.Switching lopinavir/ritonavir to atazanavir/ritonavir vs"/>
  <result pre="mechanisms of heart injury in patients suffered from severe acute" exact="respiratory" post="syndromeChinese J Cardiol312003727730 41WangpatharawanitP.SungkanuparphS.Switching lopinavir/ritonavir to atazanavir/ritonavir vs adding"/>
  <result pre="and azithromycinNat. Med.222020808809 44ZJ.The treatment and explanation of novel coronavirus" exact="pneumonia" post="infection from Xiehe hospital in Wuhanhttps://wwwdxycn/bbs/newweb/pc/post/426622542020 45TeragawaH.HondoT.AmanoH.HinoF.OhbayashiM.Adverse effects of"/>
  <result pre="azithromycinNat. Med.222020808809 44ZJ.The treatment and explanation of novel coronavirus pneumonia" exact="infection" post="from Xiehe hospital in Wuhanhttps://wwwdxycn/bbs/newweb/pc/post/426622542020 45TeragawaH.HondoT.AmanoH.HinoF.OhbayashiM.Adverse effects of interferon"/>
  <result pre="Xiehe hospital in Wuhanhttps://wwwdxycn/bbs/newweb/pc/post/426622542020 45TeragawaH.HondoT.AmanoH.HinoF.OhbayashiM.Adverse effects of interferon on the" exact="cardiovascular" post="system in patients with chronic hepatitis CJpn. Heart J.3719969059159057685"/>
  <result pre="effects of interferon on the cardiovascular system in patients with" exact="chronic hepatitis" post="CJpn. Heart J.3719969059159057685 46The Novel Coronavirus Pneumonia Diagnosis and"/>
  <result pre="of interferon on the cardiovascular system in patients with chronic" exact="hepatitis" post="CJpn. Heart J.3719969059159057685 46The Novel Coronavirus Pneumonia Diagnosis and"/>
  <result pre="on the cardiovascular system in patients with chronic hepatitis CJpn." exact="Heart" post="J.3719969059159057685 46The Novel Coronavirus Pneumonia Diagnosis and Treatment Plan"/>
  <result pre="patients with chronic hepatitis CJpn. Heart J.3719969059159057685 46The Novel Coronavirus" exact="Pneumonia" post="Diagnosis and Treatment Plan (Provisional 7th Edition) http://wwwnhcgovcn/yzygj/s7652m/202003/a31191442e29474b98bfed5579d5af95shtml, 2020."/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBioscience trends142020727332074550 56HoffmannM.Kleine-WeberH.SchroederS.KrugerN.HerrlerT.ErichsenS.SARS-CoV-2 cell entry depends on"/>
  <result pre="clinically proven protease inhibitorCell181202027128032142651 57ImaiY.KubaK.RaoS.HuanY.GuoF.GuanB.Angiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failureNature436200511211616001071 58HagiwaraS.IwasakaH.MatumotoS.HidakaS.NoguchiT.Effects of an angiotensin-converting enzyme inhibitor on"/>
  <result pre="Med.37200962663319114890 59BoskabadiJ.AskariV.R.HosseiniM.BoskabadyM.H.Immunomodulatory properties of captopril, an ACE inhibitor, on LPS-induced" exact="lung inflammation" post="and fibrosis as well as oxidative stressInflammopharmacology27201963964730291490 60MortensenE.M.PughM.J.CopelandL.A.RestrepoM.I.CornellJ.E.AnzuetoA.Impact of"/>
  <result pre="cardiac angiotensin-converting enzyme 2Circulation11120052605261015897343 62https://wwweshonlineorg/spotlights/esh-statement-on-covid-19/Statement of the European Society of" exact="Hypertension" post="(ESH) on hypertension,Renin angiotensin system blockers and COVID-1https://wwweshonlineorg/spotlights/esh-statement-on-covid-19/202003.12 63WilliamsB.ManciaG.SpieringW.Agabiti"/>
  <result pre="of arterial hypertension: the task force for the management of" exact="arterial hypertension" post="of the European Society of Cardiology and the European"/>
  <result pre="arterial hypertension: the task force for the management of arterial" exact="hypertension" post="of the European Society of Cardiology and the European"/>
  <result pre="Society of Hypertension: the task force for the management of" exact="arterial hypertension" post="of the European Society of Cardiology and the European"/>
  <result pre="of Hypertension: the task force for the management of arterial" exact="hypertension" post="of the European Society of Cardiology and the European"/>
  <result pre="pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in" exact="acute" post="respiratory distress syndromeCritical care (London, England)212017234 65MonteilV.KwonH.PradoP.HagelkruysA.WimmerR.A.StahlM.Inhibition of SARS-CoV-2"/>
  <result pre="clinical trial of recombinant human angiotensin-converting enzyme 2 in acute" exact="respiratory" post="distress syndromeCritical care (London, England)212017234 65MonteilV.KwonH.PradoP.HagelkruysA.WimmerR.A.StahlM.Inhibition of SARS-CoV-2 infections"/>
  <result pre="acute respiratory distress syndromeCritical care (London, England)212017234 65MonteilV.KwonH.PradoP.HagelkruysA.WimmerR.A.StahlM.Inhibition of SARS-CoV-2" exact="infections" post="in engineered human tissues using clinical-grade soluble human ACE2Cell1812020905913(e907)32333836"/>
  <result pre="soluble human ACE2Cell1812020905913(e907)32333836 66Cytokine Storm Is the Therapeutic Target of" exact="Severe" post="SARS-CoV-2 Infection2020Chinese Society of Immunologyhttp://wwwcsiorgcn/article/content/view?id=100602.06 67Dominguez-RodriguezA.Abreu-GonzalezP.MarikP.E.ReiterR.J.Melatonin, cardiovascular disease and"/>
  <result pre="Therapeutic Target of Severe SARS-CoV-2 Infection2020Chinese Society of Immunologyhttp://wwwcsiorgcn/article/content/view?id=100602.06 67Dominguez-RodriguezA.Abreu-GonzalezP.MarikP.E.ReiterR.J.Melatonin," exact="cardiovascular disease" post="and COVID-19: a potential therapeutic strategy?Melatonin Research3202031832110.32794/mr11250065 68WanS.YiQ.FanS.LvJ.ZhangX.GuoL.Characteristics of"/>
  <result pre="Target of Severe SARS-CoV-2 Infection2020Chinese Society of Immunologyhttp://wwwcsiorgcn/article/content/view?id=100602.06 67Dominguez-RodriguezA.Abreu-GonzalezP.MarikP.E.ReiterR.J.Melatonin, cardiovascular" exact="disease" post="and COVID-19: a potential therapeutic strategy?Melatonin Research3202031832110.32794/mr11250065 68WanS.YiQ.FanS.LvJ.ZhangX.GuoL.Characteristics of"/>
  <result pre="therapeutic strategy?Melatonin Research3202031832110.32794/mr11250065 68WanS.YiQ.FanS.LvJ.ZhangX.GuoL.Characteristics of lymphocyte subsets and cytokines in" exact="peripheral" post="blood of 123 hospitalized patients with 2019 novel coronavirus"/>
  <result pre="peripheral blood of 123 hospitalized patients with 2019 novel coronavirus" exact="pneumonia" post="(NCP)medRxiv202010.1101/2020.02.10.20021832(2020.2002.2010.20021832) 69ZhouY.FuB.ZhengX.WangD.ZhaoC.qiY.Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+"/>
  <result pre="pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe" exact="pulmonary" post="syndrome patients of a new coronavirusbioRxiv202010.1101/2020.02.12.945576(2020.2002.2012.945576) 70ZhouQ.The efficacy and"/>
  <result pre="GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary" exact="syndrome" post="patients of a new coronavirusbioRxiv202010.1101/2020.02.12.945576(2020.2002.2012.945576) 70ZhouQ.The efficacy and safety"/>
  <result pre="on principles of clinical management of patients with severe emergent" exact="cardiovascular" post="diseases during the COVID-19 epidemicCirculation1412020e810e81610.1161/CIRCULATIONAHA.120.04701132216640 75MadjidM.VardenyO.ACC Clinical Bulletin: Cardiac"/>
  <result pre="emergent cardiovascular diseases during the COVID-19 epidemicCirculation1412020e810e81610.1161/CIRCULATIONAHA.120.04701132216640 75MadjidM.VardenyO.ACC Clinical Bulletin:" exact="Cardiac" post="Implications of Novel Wuhan Coronavirus (COVID-19 )2020American College of"/>
  <result pre="Novel Wuhan Coronavirus (COVID-19 )2020American College of Cardiology 76LiR.PeiS.ChenB.SongY.ZhangT.YangW.Substantial undocumented" exact="infection" post="facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)Science (New"/>
 </snippets>
</snippetsTree>
